Back to the full story4 sources · Moderna’s personalized mRNA shot could reshape the fight against skin cancer◆ Analytics
Moderna’s personalized mRNA shot could reshape the fight against skin cancer
Deterministic text analytics computed across all 4 sources. Frequency, entity overlap, and claim overlap — computed counts only. Nothing is rated true or false.
01
Frequency Analytics
The most common words and exact phrases across every report in this cluster. Computed counts only.
Top words
modernacancermrnavaccinemerckpersonalizedresultssharestrialskin
Top phrases
moderna and merckcancer vaccinemoderna and merck sharesmrna cancer vaccinepersonalized mrnamerck sharesskin cancermrna cancer
02
Entity Overlap
Names detected in the report text: which appear across multiple sources, and which only one source mentions.
Across multiple sources
- Keytruda · 2 sources
- Merck · 2 sources
- Merck's · 2 sources
- Moderna · 2 sources
Unique to one source
- Moderna’s · MarketWatch
- Doctors · MarketWatch
- Trump · Axios
- COVID · Axios
- Food · Axios
- Phase · Ars Technica
- Pharmaceutical · Ars Technica
- The Phase · Ars Technica
03
Claim Overlap
Near-identical sentences found in two or more reports, versus sentences that appear in only one. Text match only — nothing is rated true or false.
Repeated across sources
No sentence appeared in more than one source.
Appears once
- "Doctors and patients are excited about the possible breakthrough, but some analysts believe there’s too much hype." · MarketWatch
- "Moderna and Merck shares soared on Wednesday after the companies said a personalized mRNA treatment hit its target of preventing skin cancer from recurring or spreading in a late-stage clinical trial." · Axios
- "Why it matters: The results come at a pivotal moment for Moderna and mRNA research, after Trump administration health officials cut federal funding for new vaccines and asserted the technology poses more risks than rewards." · Axios
- "The vaccine reportedly thwarted the cancer's return and spread." · Ars Technica
- "Pharmaceutical partners Moderna and Merck announced on Wednesday that their novel mRNA-based vaccine—individually tailored to target a patient's unique cancer mutations—was effective in a late-stage clinical trial of patients with melanoma, one of the deadliest forms of skin cancer." · Ars Technica